BTK and atrial fibrillation: In patients, ibrutinib (inhibitor of Bruton tyrosine kinase, an upstream effector of PI3Kα) increased cardiac disorders (2-fold) and atrial fibrillation (3-fold) [34], as well as instances of sudden death and ventricular arrhythmias [35,36].